Access
To read this story in full you will need to login or make a payment (see right).
Opinion
Nature 418, 353 (25 July 2002) | doi:10.1038/418353a
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
- More Challenges
- Powered by:
nature jobs
Senior Faculty Positions
- Torrey Pines Institute for Molecular Studies
- Port St. Lucie, FL
Postdoctoral Associate in Enzyme Biochemistry
- Cornell University
- Ithaca, New York
Bigger isn't always better
Abstract
The pharmaceutical industry's merger mania has done little to spur the innovation on which its future health will depend. Is it time to rethink the role of research within 'big pharma'?
In his heyday in the 1960s and 1970s, James Black demonstrated a Midas touch that turned base chemicals into pharmaceutical gold. An old-fashioned British pharmacologist who would think through his experiments for weeks before picking up a pipette, Black passionately believed in his duty to help cure disease — and in the capability of drug companies to help him do so.
To read this story in full you will need to login or make a payment (see right).
